ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
March 07, 2024 17:40 ET
|
The Rosen Law Firm PA
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between...
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024 07:00 ET
|
Biogen Inc.
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development...
PolTREG appoints Dan Shelly as Chief Business Development Officer
February 21, 2024 01:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
February 08, 2024 16:02 ET
|
Athira Pharma, Inc.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
February 07, 2024 08:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des Médicaments
January 26, 2024 12:01 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AUPRÈS DE L'AGENCE EUROPÉENNE DES...
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
January 26, 2024 12:01 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN...
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635
January 09, 2024 07:30 ET
|
Verge Genomics
VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform Verge’s proof-of-concept study...
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 08, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Muscular Dystrophy Association Announces Acosta Group’s Historic $100 Million Fundraising Milestone
December 21, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that long-term partner Acosta Group has reached a historic $100 million milestone in fundraising...